Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.
Hepatocellular carcinoma
Immunotherapy
Pharmacotherapy
Journal
Digestive diseases (Basel, Switzerland)
ISSN: 1421-9875
Titre abrégé: Dig Dis
Pays: Switzerland
ID NLM: 8701186
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
06
2021
accepted:
02
10
2021
pubmed:
14
10
2021
medline:
8
9
2022
entrez:
13
10
2021
Statut:
ppublish
Résumé
Due to the number of emerging new treatment options, the systemic treatment of hepatocellular carcinoma (HCC) is rapidly changing. We provide here an overview of the current landscape of systemic treatment of HCC and discuss its potential future development. HCC is a leading cause of tumor-related death worldwide. Despite the efforts aimed at reducing the prevalence of HCC through vaccination and antiviral treatment, and the implementation of screening programs for early tumor detection, most patients are diagnosed with or progress to advanced HCC. For approximately 10 years, sorafenib has been the only effective systemic treatment available for these patients. Recently, however, a number of new systemic compounds, comprising several multi-kinase inhibitors and immune-checkpoint inhibitors, have been approved for treatment of HCC. These new agents are opening a plethora of therapeutic options for the future therapy of HCC. The rapid progress in the treatment of HCC raises the question of the optimal combination and sequence of these agents in the treatment of patients with advanced disease. The substantial improvements in terms of objective response and survival indicate that the use of immune-checkpoint inhibitors-based treatment combinations may be extended to patients with intermediate-stage HCC.
Sections du résumé
BACKGROUND
BACKGROUND
Due to the number of emerging new treatment options, the systemic treatment of hepatocellular carcinoma (HCC) is rapidly changing. We provide here an overview of the current landscape of systemic treatment of HCC and discuss its potential future development.
SUMMARY
CONCLUSIONS
HCC is a leading cause of tumor-related death worldwide. Despite the efforts aimed at reducing the prevalence of HCC through vaccination and antiviral treatment, and the implementation of screening programs for early tumor detection, most patients are diagnosed with or progress to advanced HCC. For approximately 10 years, sorafenib has been the only effective systemic treatment available for these patients. Recently, however, a number of new systemic compounds, comprising several multi-kinase inhibitors and immune-checkpoint inhibitors, have been approved for treatment of HCC. These new agents are opening a plethora of therapeutic options for the future therapy of HCC.
KEY MESSAGES
CONCLUSIONS
The rapid progress in the treatment of HCC raises the question of the optimal combination and sequence of these agents in the treatment of patients with advanced disease. The substantial improvements in terms of objective response and survival indicate that the use of immune-checkpoint inhibitors-based treatment combinations may be extended to patients with intermediate-stage HCC.
Identifiants
pubmed: 34644705
pii: 000520095
doi: 10.1159/000520095
pmc: PMC9501734
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Sorafenib
9ZOQ3TZI87
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
565-580Informations de copyright
© 2021 The Author(s) Published by S. Karger AG, Basel.
Références
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):559-568
pubmed: 33971141
Hepatology. 2016 Jul;64(1):106-16
pubmed: 26765068
Nature. 2021 Apr;592(7854):450-456
pubmed: 33762733
Pharmazie. 2019 Nov 1;74(11):688-693
pubmed: 31739839
Gastroenterology. 2019 Jul;157(1):54-64
pubmed: 30986389
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Sci Transl Med. 2018 Jan 17;10(424):
pubmed: 29343622
United European Gastroenterol J. 2018 Aug;6(7):970-973
pubmed: 30228883
J Hepatol. 2016 Dec;65(6):1140-1147
pubmed: 27469901
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Gut. 2020 Jan;69(1):168-176
pubmed: 30878947
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
J Hepatol. 2016 Nov;65(5):1031-1042
pubmed: 27262756
Hepatology. 2020 Oct;72(4):1488-1490
pubmed: 32171041
Br J Cancer. 2021 Jul;125(2):190-199
pubmed: 33824476
Aliment Pharmacol Ther. 2019 May;49(10):1323-1333
pubmed: 30980420
Cancer Discov. 2019 Aug;9(8):1124-1141
pubmed: 31186238
Lancet Oncol. 2015 Oct;16(13):1344-54
pubmed: 26361969
J Hepatol. 2021 Sep;75(3):600-609
pubmed: 34051329
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Clin Cancer Res. 2013 Aug 1;19(15):4290
pubmed: 23766362
Gut. 2020 Oct;69(10):1887-1888
pubmed: 31611301
Clin Cancer Res. 2018 Mar 15;24(6):1287-1295
pubmed: 29298798
Cancer Res Treat. 2016 Oct;48(4):1243-1252
pubmed: 26910470
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
J Gastroenterol. 2016 Dec;51(12):1150-1160
pubmed: 27106231
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Cancer Discov. 2019 Dec;9(12):1696-1707
pubmed: 31575541
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
JAMA Oncol. 2020 Nov 01;6(11):e204564
pubmed: 33001135
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
J Clin Oncol. 2020 Sep 10;38(26):2960-2970
pubmed: 32716739
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Oncotarget. 2016 Feb 9;7(6):6639-48
pubmed: 26735891
J Hepatol. 2018 Aug;69(2):353-358
pubmed: 29704513
Hepatol Res. 2020 Jul;50(7):885-888
pubmed: 32088930
Am J Transplant. 2021 May;21(5):1979-1980
pubmed: 33316117
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32868393
Lancet Oncol. 2015 Jul;16(7):859-70
pubmed: 26095784
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Lancet Oncol. 2021 Jul;22(7):977-990
pubmed: 34143971
Nat Rev Clin Oncol. 2015 Mar;12(3):132-4
pubmed: 25687910
Nat Commun. 2017 Jun 06;8:15180
pubmed: 28585546
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543
pubmed: 33850328
Cancers (Basel). 2019 Jul 07;11(7):
pubmed: 31284682
J Hepatol. 2020 Feb;72(2):342-352
pubmed: 31954496
Lancet Oncol. 2018 May;19(5):682-693
pubmed: 29625879